Sandborn William J.'s Form 4 filing
Ventyx Biosciences, Inc. (VTYX) · filed May 16, 2023
- Accession no.
- 0001209191-23-029961
- Filed
- May 16, 2023, 7:10 PM ET
- Trade date
- May 15, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $127.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandborn William J.CIK 0001923805 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Common Stock | MOption exerciseAcquired | +3,272 | $0.20 | +$654.4 | 38,149 | Indirect | |
| May 15, 2023 | Common Stock | SSaleDisposed | −1,978 | $36.09F2 | −$71,377.71 | 36,171 | Indirect | |
| May 15, 2023 | Common Stock | SSaleDisposed | −1,309 | $36.88F3 | −$48,273.04 | 34,862 | Indirect | |
| May 15, 2023 | Common Stock | SSaleDisposed | −200 | $37.66F4 | −$7,531.5 | 34,662 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Common Stock | MOption exerciseDisposed | −3,272 | $0.00 | $0 | 20,922 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average share price of an aggregate total of 1,978 shares sold in the price range of $35.4917 to $36.4819. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average share price of an aggregate total of 1,309 shares sold in the price range of $36.545 to $37.43. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average share price of an aggregate total of 200 shares sold in the price range of $37.635 to $37.68. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Medical Officer